77 completed, 25 recruiting, 11 terminated, 10 active not recruiting. 141 Phase 1, 44 Phase 2.
Follow Skin Diseases, Vascular: new trials by email Literature Review of Skin Diseases, Vascular trials Research Report on Skin Diseases, Vascular
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines TLL-018, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 1 / Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 36 | 2026-08-15 | 2026-08-24 |
| Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases Allogeneic CD19/BCMA-targeted CAR-γδT cell injection, Cyclophosphamide, Fludarabine - Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 9 | 2026-07-01 | 2026-06-09 |
| Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2). Alpha-0261, Placebo - Chronic Spontaneous Urticaria (CSU), Healthy Volunteers | Phase 1 | Not yet recruiting | AlphaMol Science Ltd. (Shanghai) | 48 | 2026-07-01 | 2026-07-06 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) BBT001, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Recruiting | Bambusa Therapeutics | 48 | 2026-06-29 | 2026-07-22 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults EDP-978, Placebo - Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 1 | Recruiting | Enanta Pharmaceuticals, Inc | 98 | 2026-04-01 | 2026-04-21 |
| A Phase 1 Study of Cizutamig in IgE Mediated Diseases Cizutamig - IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy | Phase 1 | Withdrawn | Candid Therapeutics | 2026-04-01 | 2026-07-22 | |
| CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis CC-97540, Lymphodepletion Chemotherapy - Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 / Phase 2 | Active not recruiting | Marcela V. Maus, M.D.,Ph.D. | 12 | 2026-03-30 | 2026-09-10 |
| YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis | Phase 1 | Not yet recruiting | Children's Hospital of Fudan University | 12 | 2026-03-01 | 2026-02-27 |
| Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS) JTE-162 - Cryopyrin-associated Periodic Syndromes (CAPS) | Phase 1 | Completed | Akros Pharma Inc. | 5 | 2026-02-02 | 2026-10-09 |
| Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders Descartes-08 - Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Recruiting | Cartesian Therapeutics | 50 | 2026-01-14 | 2026-07-27 |
| CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases QT-019C - SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 12 | 2026-01-01 | 2026-01-20 |
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2025-12-01 | 2026-02-03 |
| An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus, Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-11-24 | 2026-03-04 |
| Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-11-13 | 2026-03-02 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes HRS-3095 Tablet, HRS-3095 Placebo Tablet - Chronic Spontaneous Urticaria | Phase 1 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 82 | 2025-11-10 | 2026-06-12 |
| A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria GTX-B001, Normal Saline - Healthy Subjects, Cold Urticaria | Phase 1 | Recruiting | Granular Therapeutics Limited | 72 | 2025-10-06 | 2026-09-09 |
| Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load 124I AT-01 - Cryopyrin-Associated Periodic Syndromes, Amyloidosis | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2025-09-10 | 2026-05-19 |
| A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-08-13 | 2026-10-21 |
Showing 20 of 141. Sign in to see all of them.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (38) · Chronic Urticaria (23) · Angioedemas, Hereditary (22) · Lupus Erythematosus, Systemic (22) · Urticaria (20) · Myositis (18) · Scleroderma, Systemic (17) · Granulomatosis with Polyangiitis (10) · Lupus Nephritis (10) · Vasculitis (10) · Antiphospholipid Syndrome (9) · Autoimmune Diseases (9) · Giant Cell Arteritis (8) · Arthritis, Rheumatoid (7) · Cryopyrin-Associated Periodic Syndromes (7)
Skin and Connective Tissue Diseases (141) · Skin Diseases (135) · Immune System Diseases (123) · Cardiovascular Diseases (93) · Vascular Diseases (92) · Hypersensitivity, Immediate (67) · Hypersensitivity (65) · Vasculitis (59) · Autoimmune Diseases (50) · Urticaria (49) · Systemic Vasculitis (47) · Pathological Conditions, Signs and Symptoms (45) · Pathologic Processes (41) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (38)
Cyclophosphamide (10) · fludarabine (8) · Interleukin 1 Receptor Antagonist Protein (5) · avacopan (5) · berotralstat (4) · Prednisone (3) · Rituximab (3) · bilastine (3) · tocilizumab (3) · Abatacept (2) · Complement C1 Inhibitor Protein (2) · Glucocorticoids (2) · Immunotherapy, Adoptive (2) · Methylprednisolone (2) · Moxifloxacin (2)
Amgen (6) · BioCryst Pharmaceuticals (6) · China Immunotech (Beijing) Biotechnology Co., Ltd. (5) · Shire (5) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Institute of Hematology & Blood Diseases Hospital, China (3) · KalVista Pharmaceuticals, Ltd. (3) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (3) · University of California, San Diego (3) · AO GENERIUM (2) · Allakos Inc. (2) · Astria Therapeutics, Inc. (2) · CSL Behring (2) · Celldex Therapeutics (2) · Chugai Pharmaceutical (2)
United States (64) · China (28) · Germany (16) · United Kingdom (13) · Australia (11) · Canada (10) · France (6) · Italy (5) · Spain (5) · Taiwan (5) · Bulgaria (4) · Czechia (4) · Netherlands (4) · South Korea (4) · Japan (3)
Jane C Burns, MD (2) · Joanne Collier, MBChB, FFPM, Dip Stats (OU) (2) · Adriana H Tremoulet, MD (1) · Behrouz Nikbin, MD (1) · Carol A. Langford, MD, MHS (1) · Clifton O. Bingham, III, MD (1) · Clifton O. Bingham, M.D. (1) · Cornelia D Cudrici, M.D. (1)
PMID 12384926, PMID 15201414, PMID 15334472, PMID 1538192, PMID 15577929, PMID 16375711, PMID 16899778, PMID 18645136, PMID 20093349, PMID 21642470, PMID 22129253, PMID 22294344, PMID 22393898, PMID 23773637, PMID 24105252, PMID 24323392, PMID 24980392, PMID 25223501, PMID 25426834, PMID 25858045, PMID 26016741, PMID 27080929, PMID 27143789, PMID 27923814, PMID 27980877, PMID 28118536, PMID 28225674, PMID 28335798, PMID 32248659, PMID 34020509, PMID 34117737, PMID 35086692, PMID 35659282, PMID 37287970, PMID 38287611, PMID 38294975, PMID 38973157, PMID 38993026, PMID 39445704, PMID 40158724, PMID 41794053, PMID 42532045, PMID 8237108
2023 (3), 2018 (2), 2019 (2), 2009 (1), 2014 (1), 2025 (1), R01HL079184 (1), U54AR057319 (1), ZIAAR041138-08 (1)